It is possible that PPARGC1A genetic variation, which is also associated with Parkinson’s disease, CHD, and type 2 diabetes [36–38] can affect its binding with target transcription factors and thus expression of many genes, including APOE. This evidence concerns the gene APOE and coronary artery disorder.